【作者】 徐建中； 徐立新； 赵云；

【Author】 Xu Jianzhong XU Lixin ZHOU Yun.Nantong third people’ hospital,Jiangsu,Nantong 226006

【机构】 南通市第三人民医院；

【摘要】 目的:探讨拉米夫定治疗早、中期慢性重型肝炎的疗效,观察血清 TNF-α、TGF-β₁的变化。方法:121例早、中期慢性重型肝炎患者分两组,均以综合治疗为主,治疗组加用拉米夫定100mg,每日一次,共2个月。比较两组患者治疗前后肝功能,HBeAg、HBV-DNA、TGF-β₁、TNF-α的变化,及病死率的差异。结果:治疗组患者血清 HBeAg,HBV-DNA 转阴明显高于对照组,血清总胆红素,TNF-α、TGF-β₁较对照组下降明显,病死率也下降。结论:慢性重型肝炎早、中期应该尽早应用抗病毒药物,这对减少慢性重型肝炎的病死率有益。更多还原

【Abstract】 Objective:to investigate the effect of lamivudine treatment for early and developmental chronic severe hepatitis and observe the changing of serum TGF-β1、TNF-α.Methods;from may 2000 to may 2005,a total of 121 patients with early and developmental chronic severe hepatitis were studied prospectively.Of them 56 patients were received 100 mg lamivudine per day for two months besides other routine treatments,and compared with remaining 65 patients who received routine treatments.Mortality and some serum parameter such us liver function,HBeAg,HBV-DNA,TGF-β1、TNF-α were investigated.Result:HBeAg and HBV-DNA seroconversion in treatment group was higher than that in routine group,mortality and some parameter such as serum bilirubin,TGF-β1,TNF-αwere lower in treatment group than in routine group.Conclusion:anti-virus drugs such as lamividine should be used early in early and developmental chronic severe hepatitis so that it can reduced mortality and benefits those patients.更多还原